Effectiveness and Safety of Finerenone for Diabetic Kidney Disease
Author Information
Author(s): Chen Jianyu, Xue Jisu, Chen Jiahui, Xie Tingfei, Sui Xiaolu, Zhang Yanzi, Zhang Aisha, Xu Yunpeng, Chen Jihong
Primary Institution: Affiliated Bao’an Hospital of Shenzhen, The Second School of Clinical Medicine, Southern Medical University, Shenzhen, China
Hypothesis
The study will evaluate the effectiveness and safety of finerenone in patients diagnosed with diabetic kidney disease (DKD).
Conclusion
Finerenone can effectively decrease the urine albumin-to-creatinine ratio and potentially provide cardiorenal protection for individuals with DKD.
Supporting Evidence
- Finerenone treatment significantly decreased the urine albumin-to-creatinine ratio compared to placebo.
- The risk of COVID-19 and cardiovascular events was significantly lower in the finerenone treatment group.
- Finerenone may lower the chances of end-stage kidney disease and cardiovascular mortality in individuals with DKD.
- Monitoring for hyperkalemia risk is important when administering finerenone.
Takeaway
Finerenone helps people with kidney problems from diabetes by making their urine healthier and may protect their hearts too.
Methodology
The study conducted a systematic review and meta-analysis of data from various databases, analyzing four randomized controlled trials.
Potential Biases
The four randomized controlled trials included in this study were all funded by Bayer, the manufacturer of finerenone, which may introduce potential bias.
Limitations
The analysis was limited by the number of studies included, particularly two Phase II and two Phase III trials.
Participant Demographics
Participants were adults aged 18 years or older diagnosed with type 2 diabetes and chronic kidney disease.
Statistical Information
P-Value
p<0.00001
Confidence Interval
[0.78, 0.93]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website